7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,957.11

+637.76

+0.82%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqGS - Nasdaq Real Time Price USD

Parabilis Medicines, Inc. (PBLS)

28.32 -0.38 (-1.32%)

At close: October 30 at 4:00:01 PM EDT

28.80 +0.48 (+1.69%)

After hours: October 30 at 4:23:48 PM EDT

Loading Chart for PBLS

Chart Range Bar

Interval:

In partnership with ChartIQ

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors

Parabilis Medicines (PBLS) Stock May Trade At A Premium Despite Fresh Zolucatetide Trial Updates

Parabilis Medicines (PBLS) Stock May Trade At A Premium Despite Fresh Zolucatetide Trial Updates

Parabilis Medicines (PBLS) Could Be 39% Undervalued As Zolucatetide Trial Expands

Parabilis Medicines (PBLS) Could Be 39% Undervalued As Zolucatetide Trial Expands

What Does Parabilis Medicines (PBLS) Expanding Zolucatetide Into FAP Mean?

What Does Parabilis Medicines (PBLS) Expanding Zolucatetide Into FAP Mean?

Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor Drug

Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor Drug

Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026

Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026

Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis

Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis

Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026

Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026

Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026

Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Mobilize your Website

View Site in Mobile | Classic

Share by: